Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic DermatitisMay 15, 2019 6:45 AM